You are now leaving XTANDI.com
The website you are about to visit is not owned or controlled by Astellas. Astellas are not responsible for the information or services on this site.
Tokyo, Dec. 9, 2014 – Astellas Pharma Inc. (TSE: 4503; Headquarters: Tokyo; President & CEO: Yoshihiko Hatanaka) announced that it has been selected for the third year to be included in the FTSE4Good Index, one of the world’s premier indexes for socially responsible investment.
Managed by FTSE (Financial Times Stock Exchange) Group, the FTSE4Good Index is used by investors around the world to assess best practices and social responsibility criteria to inform investment strategies. The FTSE Group applies its own criteria for selection from 2,400 companies in 23 countries. As of Sept. 30, 2014, 780 companies from around the world, including 176 Japanese companies, were selected as the constituents of this index. FTSE uses unique criteria which contain 14 themes relevant to environment, social and governance. FTSE, together with the Dow Jones Sustainability Index (DJSI), are the most recognized sustainability indexes worldwide. Astellas has been listed in the DJSI Asia Pacific for the fourth consecutive year.
Astellas is committed to striving toward sustainable enhancement of enterprise value while remaining acutely aware of our social responsibilities. This involves taking a broad view that considers business, society and humanity so the company can exist not merely as a market entity, but also as a valuable member of society. Astellas uses this approach as a cornerstone for all of its corporate activities.
Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information on Astellas, please visit our website at www.astellas.us. You can also follow us on Twitter at @AstellasUS.
This website is intended for U.S. residents only. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including those under development. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.